## 14.2.2 Secondary endpoints

### 14.2.2.12 Impact of the comorbidity-index (HCT-CI) on event free survival

Table 14.2.2.12.1: Parameter estimates: comorbidity-index (HCT-CI) on event free survival - Full Analysis Population

| Parameter | Parameter estimate | Standard Error | 95% lower confidence interval | 95% upper confidence interval | P-value (Wald) |
|---|---|---|---|---|---|
| SCT | -1.242 | 0.470 | -2.164 | -0.320 | 0.008 |
| HCT-CI | 0.330 | 0.111 | 0.113 | 0.547 | 0.003 |

SCT: allogeneic stem cell transplantation. HCT-CI = comorbidity-index as continuous value (HCT-CI)
[Reference: Sorror ML, Giralt S, Sandmaier BM, et al. Hemotopoietic cell transplantation-specific comorbidity index as an out-come predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007; 110(13). 4606-4613]

Page 1 of 1

Table 14.2.2.12.2: Hazard ratio of comorbidity-index (HCT-CI) on event free survival - Full Analysis Population

| Parameter | Hazard Ratio | Standard Error | 95% lower confidence interval | 95% upper confidence interval | P-value (Wald) |
|---|---|---|---|---|---|
| SCT | 0.289 | 0.470 | 0.115 | 0.726 | 0.008 |
| HCT-CI | 1.391 | 0.111 | 1.119 | 1.729 | 0.003 |

SCT: allogeneic stem cell transplantation. HCT-CI = comorbidity-index as continuous value (HCT-CI)
[Reference: Sorror ML, Giralt S, Sandmaier BM, et al. Hemotopoietic cell transplantation-specific comorbidity index as an out-come predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007; 110(13). 4606-4613]

Page 1 of 1